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Objectives: It is not known whether the results Of randomized trials 
comparing coronary artery bypass grafting to percutaneous transluminal  
coronary angioplasty for initial revascularization apply to repeat revascu- 
larization in patients with prior bypass grafts. We studied the differences 
between the patients with prior bypass grafts referred for surgery or 
angioplasty to identify the clinical and angiographic haracteristics that 
correlated best with either choice and to find clues that might aid in 
selecting one treatment over the other. Methods: Between 1992 and 1904, 
870 patients underwent first isolated reoperation and 793 patients under- 
went first balloon angioplasty after a previous operation. A jeopardy score 
(0 to 8 points) was derived for each patient on the basis of the relative size 
of the ischemic territory. Clinical and angiographic data were analyzed for 
association with the revascularization strategy. Results: The following 
characteristics were more prevalent in the reoperation group: male sex, 
diabetes, hypertension, valvular disease, normocholester01emia, andsevere 
left ventricular systolic dysfunction; fewer functioning venous and arterial  
grafts: and a higher jeopardy score (p < 0.01 for all) than in the angioplasty 
group. A higher jeopardy score, diabetes, and a lower number of function- 
ing arterial  or venous grafts were strong, independent predictors Of referral 
for reoperation (p < 0.01 for all). In-hospital death and Q-wave infarction 
(p < 0.01 for both) were more frequent in the reoperation group. Conclu- 
sions: Reoperation was the revascularization procedure of choice when 
larger regions of myocardium were in jeopardy. Angioplasty was more 
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frequently chosen in the presence of a patent arterial graft to the left 
anterior descending coronary artery or multiple functioning bypass grafts. 
Reoperation was associated with a higher risk of in-hospital complications 
than angioplasty. (J Thorac Cardiovasc Surg 1997;114:153-61) 
A lthough coronary artery bypass grafting (CABG) and percutaneous transluminal coronary angio- 
plasty (PTCA) are effective treatments for primary 
coronary revascularization, both treatments are as- 
sociated with increased risk and reduced efficacy in 
patients with prior bypass operations. CABG pro- 
vides excellent symptomatic relief for patients with 
ischemic heart disease, and it provides better sur- 
vival results than does medical therapy in patients 
with extensive coronary disease and left ventricular 
dysfunction. 1 However, the progression of athero- 
sclerosis in native vessels and the development of 
obstructive lesions in saphenous vein bypass con- 
duits diminishes the efficacy of revascularization 
over time, resulting in cardiac events and the need 
for repeat revascularization. It is estimated that only 
approximately half of venous bypass grafts remain 
functional 10 years after the operation 2 and that up 
to 31% of surviving patients require repeat revascu- 
larization within 15 years after the initial operation) 
Eight recently completed randomized trials 4-11 
compared the effectiveness of PTCA and CABG for 
primary revascularization i patients eligible for 
both strategies. Death and myocardial infarction 
rates were equivalent for both therapies during 
follow-up periods of i to 5 years. However, it is not 
known whether these results are applicable to pa- 
tients with previous CABG. 
Compared with patients having primary CABG, 
those undergoing reoperation face a greater isk of 
mortality and morbidity, experience less relief of 
angina, and have a lower 10-year survival) On the 
other hand, the utility of PTCA for aged saphenous 
vein graft lesions is limited by a higher restenosis 
rate than that encountered in the treatment of 
native coronary arteries, despite a technical success 
rate greater than 90%. 12 
The clinical dilemma posed by the patient with 
prior CABG and recurrent ischemic symptoms i the 
choice between achieving more comprehensive and 
durable revascularization with repeat CABG, at an 
increased immediate risk, and obtaining a less com- 
plete and durable revascularization, at a lower pro- 
cedural risk. We hypothesized that these patients 
are triaged to PTCA or reoperafion on the basis of 
differences in baseline demographic characteristics, 
angiographic features, and procedural risk. We then 
set out to identify the factors that best correlated 
with the choice of revascularization procedure in 
patients with prior CABG. 
Methods 
Patients. All patients who had first isolated repeat 
CABG at the Cleveland Clinic Foundation between Jan- 
uary 1992 and December 1994 were identified through the 
Cardiovascular Information Registry. This registry con- 
tains prospectively collected ata, including demographic 
characteristics, coexistent chronic disease, coronary risk 
factors, qualitative angiographic findings (including the 
presence and patency of bypass grafts from previous 
operations), echocardiographic assessments of coexistent 
valvular disease, surgical details (conduits used and anas- 
tomoses performed), and in-hospital outcome (death and 
morbidity). We excluded patients (n = 105) who either 
had PTCA before the second operation or had a concom- 
itant valvular or other cardiac procedure during the 
second operation. 
All patients with symptomatic coronary atherosclerosis 
who had one prior CABG and who were referred for a 
first percutaneous coronary intervention between Novem- 
ber 1992 and December 1994 were identified through the 
Cardiology Interventional Database at the same institu- 
tion, This database contains prospectively collected ata 
on demographic characteristics, coronary risk factors, 
qualitative and quantitative angiography before and after 
intervention, and in-hospital outcome (death and myocar- 
dial infarction). Patients unsuitable for surgical revascu- 
larization (n = 23) were excluded. 
Definitions. The coronary risk profile encompassed the 
following: hypertension (blood pressure > 140/90 mm Hg 
or antihypertensive th rapy), hypercholesterolemia (total 
cholesterol level > 5.2 mmol/L or cholesterol-lowering 
therapy), diabetes mellitus necessitating therapy (oral 
hypoglycemic agents or insulin), family history of prema- 
ture symptomatic coronary artery disease (myocardial 
infarction or revascularization in male relatives younger 
than age 45 years or in female relatives younger than age 
55 years), and smoking within 1 year of the procedure. 
PTCA, as used here, refers to any percutaneous coro- 
nary intervention i which balloon angioplasty or newer 
devices, such as atherectomy or intravascular stents, were 
used. 
PTCA success was defined as reducing the diameter of 
the stenosis to less than 50%, as determined by hand-held 
calipers, in all attempted lesions, in conjunction with 
Thromb01ysis in Myocardial Infarction (TIMI) flow grade 
III. In the PTCA group, postprocedural myocardial in- 
farction was defined as a peak creatine kinase MB fraction 
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Table I. Computation of the jeopardy score for characterizing the area of myocardium with impaired 
circulation (modified from Califf and associates 14) 
Arterial system supplying 
myocardial territory Score Comments 
Right 2 Maximum score for right coronary system, including branches 
Posterior descending 1 
Posterior ventrieular 1 
Right ventricular 1 
Left main trunk 1 
Left anterior descending 3 
Proximal, midportion 2 
Distal 1 
Diagonal branches 1 
Left circumflex 3 
Proximal 2 
Midportion 1 
Obtuse marginal (each) 1 
Applies only in patients inthe PTCA group with open LAD grafts and jeop- 
ardized iagonal branches 
Maximum leff anterior descending system score, including branches. All 
grafts were considered to be placed in the midportion of the vessel. 
Maximum left circumflex system score, including branches 
greater than 30/xg/ml (normal range: 0 to 5/xg/L), with or 
without new significant Q waves (-> 0.04 second or > 1/4 of 
the R-wave amplitude in at least wo contiguous leads). In 
the CABG group, myocardial infarction was defined as 
new significant Q waves or loss of R-wave amplitude and 
a creatine kinase MB fraction greater than 10% of an 
elevated total creatine kinase level. Creatine kinase mea- 
surements were obtained routinely in all patients after the 
revascularization procedure. 
Angiographic and eehoeardiographic data. When the 
diameter of the stenosis, as assessed visually, was greater 
than 60%, native and graft lesions were classified as 
causing ischemia. Left ventricular systolic function was 
graded visually, according to the estimated ejection 
fraction, as normal (>60% ejection fraction), mildly im- 
paired (50% to 60% ejection fraction), moderately 
impaired (30% to 49% ejection fraction), or severely 
impaired (<30% ejection fraction). Clinically important 
valvular disease was defined as any defect resulting in 
grade 3 (moderate) or 4 (severe) on a scale of 1 to 4.13 
Jeopardy score. The jeopardy score is a modification of 
the score described by Califf and associates. 14It is based 
on the proportion of myocardium supplied by native 
coronary arteries or bypass grafts with flow-limiting ste- 
noses, without accounting for lesion structure (Table I). 
The maximum score, 8 points, indicates patients with the 
largest burden of ischemia. We assumed that all revascn- 
larization procedures were applied to viable myocardium. 
The territory supplied by the right coronary artery was 
assigned a maximum score of 2 points, corresponding to
the two terminal branches of this artery. Grafts to the 
distal right coronary artery were assigned points according 
to the patency status of the distal branches. The territory 
of the left anterior descending coronary artery, including 
the myocardium supplied by the diagonal branches, was 
assigned a maximum score of 3 points. We assumed that 
all bypasses to the left anterior descending coronary artery 
were placed in the midportion of the vessel. The territory 
Table II. Baseline characteristics of 1663 patients 
with a history of isolated CABG undergoing repeat 
revascularization with CABG or PTCA 
CABG PTCA 
Variable (n = 870) (n = 793) p Value 
Age 64 + 8 65 -+ 9 0.19 
Men 85 77 0.01 
Hypertension 66 56 0.01 
Diabetes mellitus 48 28 0.01 
Hypercholesterolemia 31 46 0.01 
(>200 mg/dl) 
Interval from first CABG 10.6 _+ 4.4 7.7 _+ 5.4 0.01 
Functional grafts per patient 1.0 -+ 0.3 1.6 _+ 0.5 0.01 
Patent ITA graft to LAD 4t 55 0.01 
Jeopardy score 3.6 _+ 1.3 1.9 _+ 0.9 0.01 
Severe LV dysfunction 40 28 0.01 
Important valvular disease 11 3 0.01 
Data presented as mean _+ standard deviation oras percent. ITA, Internal 
thoracic artery graft; LAD, left anterior descending coronary artery; LV, 
left ventricular. 
of the left circumflex artery, including the contribution of
the obtuse marginal branches, was assigned a maximum 
score of 3 points. Because most distal anastomoses in this 
system do not involve the left circumflex artery trunk per 
se, all bypass grafts to this system were categorized as 
supplying the area of an obtuse marginal branch. 
Data management and statistical analysis. After ab- 
straction from the original registries, the two populations 
were consolidated in one database. Continuous variables 
were compared with the Wilcoxon rank-sum test and 
categoric values were compared with the X 2 test or 
Fisher's exact est. Multivariate logistic regression model- 
ing was performed to detect any independent association 
between the method of repeat revascularization a d clin- 
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p<0,001 for the trend 
0-2 3-4 >4 
Jeopardy score 
Fig. 1. Distribution of jeopardy scores in the reoperation (white bars) and angioplasty (black bars) groups. 
Table III. Distribution of saphenous vein grafts by degree of stenosis and graft location in 1663 patients before 
repeat revascularization with CABG* or PTCA 
<60% stenosis 60%-99% stenosis Occluded 
CABG PTCA CABG PTCA CABG PTCA 
Ane~ (%) (%) (%) (%) (%) (%) 
Right coronary artery 26 44 
Left anterior descending artery 30 63 
Left circumflex artery 22 46 
p Value <0.001, all arteries 
20 18 52 38 
29 11 41 26 
25 20 53 34 
>0.2, all arteries <0.001, allarteries 
Data presented as percentage of total grafts per artery. 
*Based on graft patency data in 798 patients (91.7%). 
ical and angiographic variables. A 0.05 level of signifi- 
cance was used for all tests, and two-tailed comparisons 
were employed. All analyses were performed with the 
SAS software package (version 6.08). is 
Results 
Study population. The 870 consecutive patients 
who underwent isolated second CABG during the 
study form the reoperation (CABG) group. The 
PTCA group consisted of 793 consecutive patients 
with a first percutaneous intervention after an initial 
CABG operation. In 502 patients (63%) having 
PTCA, the treated vessels included only native 
coronary arteries; in the other 291 patients (37%), at 
least one graft was treated. 
The baseline characteristics of the two groups are 
given in Table II. The mean age was similar between 
the CABG and PTCA groups. Compared with the 
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PTCA group, the surgical cohort had a higher 
proportion of male, diabetic, and hypertensive pa- 
tients. In general, the interval between revascular- 
izations was longer in the CABG group (10.6 _+ 4.4 
vs 7.7 ± 5.4 years, respectively, p < 0.01). The 
incidence of severe left ventricular systolic dysfunc- 
tion and important valvular disease in the CABG 
group significantly exceeded that of the PTCA 
group. 
Jeopardy scores. The distributions of the jeop- 
ardy scores in the CABG and PTCA groups are 
shown in Fig. 1. The mean (± standard eviation) 
score was significantly higher in the CABG than in 
the PTCA group (3.62 _+ 1.3 vs 1.88 ± 0.9,p < 0.01). 
Patients with and without treated diabetes mellitus 
had similar jeopardy scores in the PTCA group 
(1.85 + 0.93 vs 1.89 ± 0.85, p = 0.49) and in the 
CABG group (3.60 _+ 1.23 vs 3.65 _+ 1.29,p = 0.38). 
In the PTCA cohort, the jeopardy score for the 
502 patients who underwent native coronary artery 
PTCA (1.89 ± 0.8) was not significantly different 
from that of the 291 patients with graft PTCA 
(1.87 ± 1.0, p = 0.72). Patients with and without at 
least moderate left ventricular systolic dysfunction 
had identical mean jeopardy scores (1.88 ± 0.9 in 
both groups, p = 0.96). In contrast, patients with 
successful PTCA (n = 692) had a lower mean 
jeopardy score than those (n = 101) with failed or 
partially successful PTCA (1.84 ± 0.9 vs 2.1 ± 0.9, 
p = 0.006). 
Characteristics of first CABG conduits. The dis- 
tribution of patent, diseased, and occluded saphe- 
nous vein grafts to the various native coronary 
arteries before the index procedure captured in this 
study is shown in Table III. Patients in the CABG 
group had a significantly lower proportion of func- 
tional (diameter stenosis < 60%) saphenous vein 
grafts than those in the PTCA group. Similarly, 41% 
and 55% of patients in the CABG and PTCA 
groups, respectively, had functional internal thoracic 
artery grafts to the left anterior descending coronary 
artery (p < 0.001). Overall, the patients in the 
CABG group (data on graft patency were not 
available for 72 patients [8.3%]) had 1.0 ± 0.3 
functional grafts, whereas those receiving PTCA 
had 1.6 ± 0.5 patent grafts (p < 0.01), despite a 
similar number of grafts placed at the initial CABG 
(2.9 ± 1.0 in both groups, p = 0.48). 
Determinants of revascularization method. The 
method of repeat revascularization was modeled 
with the variables of age, gender, coronary risk 
profile, presence of severe left ventricular systolic 
Table IV. Results of multiple logistic regression 
analysis for predicting the choice of CABG or PTCA 
Variable Odds ratio 95% CI p Value 
Jeopardy score 3.8* 3.2-4.5 0.001 
Diabetes mellitus 2.9 2.0-4.2 0.001 
Valvular disease 2.9 1.4-6.2 0.006 
Functional ITA graft to LAD 0.6 0.4-0.8 0.002 
Number of functional grafts 0.6t 0.5-0.7 0.001 
Jeopardy score, diabetes, and valvular disease were associated with referral 
to CABG, and functional internal thoracic artery grafts and total number 
of functional grafts were associated with referral to PTCA. C/, Confidence 
interval; ITA, internal thoracic artery; LAD, left anterior descending 
coronary artery. 
*For 1 point increment. 
tFor 1 additional functional graft. 
dysfunction, presence of clinically important valvu- 
lar disease, jeopardy score, a functional arterial graft 
to the left anterior descending coronary artery, and 
the number of functional grafts (Table IV). 
A higher jeopardy score was directly, indepen- 
dently, and strongly associated with repeat CABG, 
rather than with PTCA. The odds of undergoing 
repeat CABG increased 3.8-fold (95% confidence 
interval 3.2 to 4.5) for each 1 point increase in score 
(Table IV). The other variables ignificantly associ- 
ated with repeat CABG rather than PTCA were the 
presence of diabetes and important valvular heart 
disease. In contrast, a functional internal thoracic 
artery graft to the left anterior descending coronary 
artery and a higher number of functional grafts were 
more likely to be associated with PTCA rather than 
repeat CABG (p < 0.002 for both). Age, gender, 
hypertension, and severe left ventricular systolic 
dysfunction were not significantly associated with 
the method of repeat revascularization i this 
model. 
In-hospital outcome. The patients in the PTCA 
group had angioplasty at 1.6 ± 0.9 sites, whereas the 
patients undergoing CABG had a mean of 2.9 ± 1.0 
distal anastomoses. Both these values compare fa- 
vorably with the preintervention jeopardy scores of 
1.88 +_ 0.9 and 3.62 + 1.3, respectively. The main 
events after revascularization are summarized in 
Fig. 2. Forty-two patients (4.8%) died after repeat 
CABG, compared with four (0.5%) after PTCA 
(p < 0,001). Q-wave myocardial infarctions oc- 
curred in 11 (1.4%) patients in the PTCA and in 32 
(3.7%, p = 0.005) patients in the CABG group. An 
additional 66 (8.3%) patients undergoing PTCA had 
non-Q-wave infarctions; the rate of this event could 
not be determined in the patients having CABG. 
The incidence of any myocardial infarction was not 
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Death Q-wave MI 
p=0.0O5 
Fig. 2. In-hospital death and Q-wave infarction (MI) in the reoperation (white bars) and angioplasty (black 
bars) groups. 
significantly higher in patients who had graft PTCA 
than in those who had native-vessel PTCA: 12.0% 
(35/291 patients) and 8.4% (42/502 patients), re- 
spectively (p = 0.13). In 101 (12.7%) patients un- 
dergoing PTCA, the procedure failed or was only 
partially successful, and three (0.4%) patients re- 
quired emergency CABG. Thirty (3.4%) patients 
undergoing reoperation eeded reexploration for 
bleeding. Neurologic and respiratory complications 
(prolonged intubation, infection, tracheostomy) 
were noted in 2.1% and 13.8% of the CABG cohort, 
respectively. 
Discuss ion 
This large series of consecutive patients who 
previously underwent CABG and again became 
candidates for revascularization yielded consider- 
able insight into the determinants for the choice of 
the revascularization strategy. By using a simple 
scoring system to estimate the extent of myocardium 
at risk, we found that the patients referred for 
repeat CABG had a much larger proportion of 
myocardium that could be revascularized than did 
patients referred for PTCA. In-hospital mortality 
and Q-wave myocardial infarction were significantly 
more common after repeat CABG than after PTCA. 
In two thirds of the PTCA group, progression of 
native coronary atherosclerosis was implicated in caus- 
ing new symptoms. The greater incidence of progres- 
sive coronary atherosclerosis rather than vein graft 
disease in this group resulted in a shorter interval 
between revascularization episodes than for the 
CABG group. The combination of baseline character- 
istics, coronary risk factors, and graft patency in a 
multivariate r gression model further underscored the 
independent association of a higher jeopardy score, 
diabetes, and coexisting valvular disease with referral 
to CABG for revascularization. A patent arterial graft 
to the left anterior descending coronary artery and a 
higher number of functional grafts were directly linked 
to PTCA as a revascularization strategy. Interestingly, 
age, gender, and severe left ventricular systolic dys- 
function were not statistically related to either method 
of revascularization. 
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Repeat revascularization series. Surgical revas- 
cularization in patients with previous CABG is 
technically more challenging and is associated with a 
higher incidence of morbidity than the initial inter- 
vention. Three series 3' 16, 17 confirmed the emer- 
gence of vein graft atherosclerosis as the main 
indication for reoperation. 
We reviewed CABG reoperations over a 20-year 
period (1967 to 1987) and provided in-hospital 
outcome and 10-year survivals. 3The annual hospital 
mortality for 2509 consecutive patients fluctuated 
between 2% and 5%. Over time, the candidates for 
reoperation became older and the interval between 
operations lengthened (10 years in the most recent 
cohort). In the intervening years, one third of pa- 
tients lost previously normal left ventricular func- 
tion. During the same period, however, advances in 
operative technique provided new advantages. Im- 
proved myocardial protection during surgery is cred- 
ited with reducing by half the perioperative Q-wave 
infarction rate, bringing it to 4%. Improved graft 
patency was achieved with the increasing use of 
internal thoracic artery grafts in patients undergoing 
reoperation, reaching a prevalence of 67%. Simul- 
taneously, the increased prevalence of older patients 
and important left main coronary artery narrowing 
adversely influenced long-term survival. Character- 
istics associated with improved survival included age 
younger than 65 years and the following preopera- 
tive variables: no comorbidity, mild angina, no sig- 
nificant left main coronary artery disease, good left 
ventricular function, and placement of an internal 
thoracic artery graft to the anterior descending 
coronary artery in the first or second operation. The 
overall 10-year survival and event-free survival were 
69% and 41%, respectively. 
Weintraub and colleagues 16recently analyzed the 
Emory University experience with reoperation i 2030 
patients. In-hospital mortality was 5.7% in elective 
reoperations, and Q-wave infarctions were noted in 
5.6%. Increased age, emergency surgery, and de- 
pressed left ventricular function were significant pre- 
dictors of adverse outcome. One year after reopera- 
tion, 22% of patients had died, had had a myocardial 
infarction, or had had another evascularization pro- 
cedure. Twelve years after reoperation, 54% of the 
patients were alive, and 84% had had a myocardial 
infarction or repeat revascularization. 
Akins and coworkers 17 reviewed the reoperation 
experience at Massachusetts General Hospital from 
1977 through 1992, reporting 5.3% mortality and 
6.2% myocardial infarction rates in 750 patients. 
The efficacy of PTCA is also affected by a previous 
CABG operation. Lesions in saphenous vein grafts 
present a particular challenge because of the pres- 
ence of concentric, diffuse atheromata nd a ten- 
dency for distal embolizationJ s These characteris- 
tics result in somewhat lower procedural success 
rates (75% to 97%, mean 88%) than in native 
coronary angioplasty, 19despite the use of newer 
devices with debulking capability. 2°-22 Nevertheless, 
the proportion of patients dying (0% to 5%, mean 
0.7%) or having a myocardial infarction (0% to 9%, 
mean 3.4%) remains consistently low under these 
conditions. The high rate of restenosis after PTCA 
for late saphenous vein bypass narrowing is the 
principal deterrent o its more widespread use. 
Angiographic restenosis rates of 45% to 60% are 
commonly reported, reflecting mostly the experi- 
ence with balloon angioplasty and directional 
atherectomy. 12 The outcome of PTCA in native 
coronary arteries after previous CABG appears to 
be equivalent to the results of angioplasty inpatients 
without a previous CABG. The exception is failed 
angioplasty complicated by ongoing ischemia or 
hemodynamic instability, for which emergency reop- 
eration is highly hazardous. 23
Randomized primary revascularization trials. A 
metaanalysis of eight randomized trials comparing 
PTCA with CABG for primary revascularization 
found substantial similarity of outcome across the 
published studies. 24 The two revascularization strate- 
gies yielded the same prognosis for survival and sub- 
sequent myocardial infarction. In an average 3-year 
follow-up, the two strategies differed significantly in 
their requirements for repeat revascuiarization: 33.7% 
for those initially assigned to PTCA and 3.3% for 
those assigned to CABG. Not included is the report of 
the Bypass Angioplasty Revascularization I vestiga- 
tion (BARI), which found marked differences in the 
diabetes subset, favoring CABG. 2s Overall, 30% of all 
patients undergoing PTCA in the BARI received 
CABG during the first 5 years of follow-up. 
The aforementioned deficiencies of repeat revas- 
cularization ushered in the search for alternative 
strategies. In the field of coronary bypass surgery, 
improved methods of myocardial protection and 
increased use of arterial bypass grafts have im- 
proved survival and freedom from cardiac events. 
As for angioplasty, the advent of new interventional 
devices, especially stents, 26 and the development of
novel adjunctive antiplatelet agents 27 have improved 
the immediate procedural outcome and reduced the 
need for repeat revascularization. 
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Limitations. Besides the inherent limitations of 
retrospective analyses and lack of documentation of 
the decision-making process, the lack of systematic, 
functional evaluation of myocardium at risk dimin- 
ishes the validity of the jeopardy score used in this 
study. Moreover, we do not have detailed anglo- 
graphic descriptions of the lesion location in bypass 
grafts, which may have influenced the choice of 
revascularization. It is possible that a referral bias 
favoring angiop!asty existed in patients with patent 
internal thoracic artery grafts, such that bypass 
surgery was not even considered in these patients, 
even though technically feasible. Yet the data pre- 
sented are pertinent to the practice of cardiovascu- 
lar medicine outside randomized totals and provide 
a unique attempt to determine the patient charac- 
teristics relevant to treatment selection. 
Conclusion 
Among 1663 consecutive candidates for repeat 
revascularization, patients with larger areas of isch- 
emic myocardium, diabetes, and moderate valvular 
dysfunction were considerably more likely to un- 
dergo repeat CABG than PTCA. A patent internal 
thoracic artery graft to the left anterior descending 
coronary artery and a higher number of functional 
grafts were more often associated with referral to 
PTCA than to CABG. Poor left ventricular systolic 
function, advanced age, and other baseline charac- 
teristics were not associated with preferential use of 
either strategy. Periprocedural death and myocar- 
dial infarction were more common after repeat 
CABG. These observations reinforce the need for a 
randomized trial of secondary revascularization to 
resolve the clinical dilemma posed by patients with 
progressive native coronary and vein graft athero- 
sclerosis. 
We thank Dawn M. Dykstra, BSc, for the statistical 
analyses, and Kathy Vaughn, for secretarial assistance. 
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